| Hoffmann-La Roche29 programs in shared conditions | 16 · 7 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative +13 | trontinemab, inavolisib, giredestrant +7 | - Pfizer’s tucatinib added to pertuzumab (US rights: Hoffmann-La Roche) (Breast Neoplasms, NCT05132582)
- Hoffmann-La Roche’s giredestrant added to palbociclib (US rights: Pfizer) (Breast Neoplasms, NCT04546009)
- Hoffmann-La Roche’s inavolisib in a combination vs palbociclib (US rights: Pfizer) (Breast Neoplasms, NCT03424005)
- and 6 more
|
| Merck & Co., Inc26 programs in shared conditions | 22 · 8 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative +19 | patritumab deruxtecan, sacituzumab tirumotecan, molnupiravir +7 | - Merck & Co., Inc’s sacituzumab tirumotecan vs tisotumab vedotin (US rights: Pfizer) (Uterine Cervical Neoplasms, NCT06459180)
- Merck & Co., Inc’s patritumab deruxtecan added to Epirubicin (US rights: Pfizer) (Breast Neoplasms, NCT06797635)
- Merck & Co., Inc’s sacituzumab tirumotecan added to Epirubicin (US rights: Pfizer) (Breast Neoplasms, NCT06966700)
- and 5 more
|
| Eli Lilly and Company36 programs in shared conditions | 20 · 8 with both in phase 3Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colitis, Ulcerative +17 | donanemab, tersolisib, Imlunestrant +8 | - Pfizer’s berobenatide vs Tirzepatide (US & EU rights: Eli Lilly and Company) (Obesity, NCT07845500)
- Pfizer’s atirmociclib in a combination vs abemaciclib (US & EU rights: Eli Lilly and Company) (Breast Neoplasms, NCT06760637)
- Eli Lilly and Company’s tersolisib added to palbociclib (US rights: Pfizer) (Breast Neoplasms, NCT07174336)
- and 1 more
|
| Bristol-Myers Squibb23 programs in shared conditions | 12 · 6 with both in phase 3Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Multiple Myeloma +9 | xanomeline, trospium, trospium chloride +7 | - Pfizer’s elranatamab vs elotuzumab (US & EU rights: Bristol-Myers Squibb) (Multiple Myeloma, NCT06152575)
- Pfizer’s tivunatamig in a combination vs Nivolumab (US & EU rights: Bristol-Myers Squibb) (Stomach Neoplasms, NCT07392892)
|
| Novartis32 programs in shared conditions | 10 · 2 with both in phase 3Breast Neoplasms, Prostatic Neoplasms, Chronic Urticaria +7 | Alpelisib, remibrutinib, actinium AC-225 vipivotide tetraxetan +1 | - Pfizer’s atirmociclib in a combination vs Everolimus (EU rights: Novartis) (Breast Neoplasms, NCT06105632)
- Pfizer’s atirmociclib in a combination vs ribociclib (US & EU rights: Novartis) (Breast Neoplasms, NCT06760637)
|